Literature DB >> 7814368

Expression and folding of recombinant bovine prethrombin-2 and its activation to thrombin.

E E DiBella1, M C Maurer, H A Scheraga.   

Abstract

Bovine prethrombin-2 has been produced in Escherichia coli using a T7 expression system. The expressed prethrombin-2 formed intracellular inclusion bodies which were solubilized by reversible sulfonation of the cysteines in the presence of 7 M guanidine hydrochloride. Sulfonated prethrombin-2 was refolded in the presence of 4 M guanidine hydrochloride, using oxidized and reduced glutathione as the redox couple. The folded protein was purified by heparin affinity chromatography and activated to thrombin with Echis carinatus snake venom. The resulting thrombin was also purified by heparin affinity chromatography. Kinetic constants were determined for the hydrolysis of H-D-phenylalanyl-L-pipecolyl-L-arginine-p-nitroaniline by recombinant thrombin (kcat = 123 +/- 10 s-1 and Km = 2.91 +/- 0.3 microM). These values are in good agreement with those determined for wild-type thrombin (kcat = 97 +/- 8 s-1 and Km = 2.71 +- 0.25 microM). From the thrombin-mediated release of fibrinopeptide A from fibrinogen, kcat/Km was found to be the same for recombinant (17.3 +/- 1.2 microM-1 s-1) and wild-type (16.7 +/- 2.0 microM-1 s-1) thrombin. These results, taken together with circular dichroism spectra and the elution position of prethrombin-2 from a heparin affinity resin, indicate that prethrombin-2 was folded into a conformation similar to that of the wild-type protein. In addition, since E. coli produces deglycosylated enzymes, these findings suggest that the carbohydrate on the B chain of wild-type thrombin does not affect the amidolytic and fibrinolytic activities of thrombin. Finally, this expression system can be used to prepare mutants of prethrombin-2 for future structure-function studies involving thrombin and its substrates; some preliminary results of this type are presented here.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7814368     DOI: 10.1074/jbc.270.1.163

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  WEDGE: an anticoagulant thrombin mutant produced by autoactivation.

Authors:  D C Wood; L A Pelc; N Pozzi; M Wallisch; N G Verbout; E I Tucker; A Gruber; E Di Cera
Journal:  J Thromb Haemost       Date:  2014-11-29       Impact factor: 5.824

2.  Probing light chain mutation effects on thrombin via molecular dynamics simulations and machine learning.

Authors:  Jiajie Xiao; Ryan L Melvin; Freddie R Salsbury
Journal:  J Biomol Struct Dyn       Date:  2018-03-02

3.  Amide H/2H exchange reveals a mechanism of thrombin activation.

Authors:  Julia R Koeppe; Elizabeth A Komives
Journal:  Biochemistry       Date:  2006-06-27       Impact factor: 3.162

4.  Autoactivation of thrombin precursors.

Authors:  Nicola Pozzi; Zhiwei Chen; Fatima Zapata; Weiling Niu; Sergio Barranco-Medina; Leslie A Pelc; Enrico Di Cera
Journal:  J Biol Chem       Date:  2013-03-06       Impact factor: 5.157

Review 5.  Thrombin.

Authors:  Enrico Di Cera
Journal:  Mol Aspects Med       Date:  2008-02-01

6.  Crystal structure of wild-type human thrombin in the Na+-free state.

Authors:  Daniel J D Johnson; Ty E Adams; Wei Li; James A Huntington
Journal:  Biochem J       Date:  2005-11-15       Impact factor: 3.857

7.  Light Chain Mutation Effects on the Dynamics of Thrombin.

Authors:  Dizhou Wu; Jiajie Xiao; Freddie R Salsbury
Journal:  J Chem Inf Model       Date:  2021-01-15       Impact factor: 4.956

8.  Vortex Fluidic Mediated Oxidative Sulfitolysis of Oxytocin.

Authors:  Emily M Crawley; Scott Pye; Briony E Forbes; Colin L Raston
Journal:  Molecules       Date:  2022-02-07       Impact factor: 4.411

Review 9.  Are apolipoprotein E fragments a promising new therapeutic target for Alzheimer's disease?

Authors:  Filomena Lo Vecchio; Paola Bisceglia; Bruno Pietro Imbimbo; Madia Lozupone; Raffaela Rita Latino; Emanuela Resta; Maurizio Leone; Vincenzo Solfrizzi; Antonio Greco; Antonio Daniele; Mark Watling; Francesco Panza; Davide Seripa
Journal:  Ther Adv Chronic Dis       Date:  2022-03-17       Impact factor: 5.091

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.